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Abstract. Epigenetic variation represents a mechanism of regulation for genes 
expressed in different cancer histotypes. We considered breast cancer, and in-
vestigated  differential  expression  following  treatment  with  the  5-Aza-2'-
deoxycytidine  or  DAC,  a  demethylating  agent.  Several  oncogenic  signalling 
pathways  altered upon DAC treatment were detected with significant enrich-
ment, and a regulatory map integrating Transcription Factors and microRNAs 
was derived. The ultimate goal is deciphering the potential molecular mechan-
isms induced by DAC therapy in MCF7 cells.
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1 Introduction
Recent advances in the field of epigenetics have provided new insights of global epi-
genetic modifications that promote cancer development and progression [1- 8]. Not-
ably, epigenetic therapy, which is a consequence of the reversible nature of the epi-
genetic changes that alter gene expression in many tumor histotypes [9, 10], is the ul-
timate interest of our proposed research. Among several drugs with anti-tumorigenic 
effect  regulating  the  epigenetic  status  of  cells,  the  5-Aza-2'-deoxycytidine  (DAC, 
Dagogen) is considered here.  DAC is a potent demethylating agent known for an-
ti-leukemic effect in the mouse model [11- 14]. Also, DAC acts to correct epigenetic 
defect including reactivation of tumor suppressor genes (TSG) [15] silenced by epi-
genetic mechanisms in tumor tissues [2, 8]. Various phase II  trials have demonstrated 
substantial DAC activity in patients with relapsed or untreated Acute Myeloid Leuk-
emia (AML) [16, 17]. Combining DAC with a chemotherapeutic agent (Carboplatin) 
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in patients with recurrent, platinum-resistant, Epithelial Ovarian Cancer (EOC), was 
shown to exert a potent demethylating effect justifying the need of further testing for 
clinical efficacy [18]. The DAC effect was evaluated in breast cancer (BC) cell lines 
by gene expression analysis: two DAC concentrations (5 µM and 10 µM) were used, 
which revealed a role for treatment in different cellular processes linked to TNF-α-de-
pendent apoptosis [19]. In colon cancer (CC) cell lines, activation of a set of hyper-
metilated genes and transcriptional down-regulation were observed [20, 21].
In our work, the goal is to investigate the effect of DAC treatment in MCF-7 BC 
cell lines. We look into two main directions: pathway signatures and regulatory net-
works. We thus performed gene expression profiling to identify epigenetically modi-
fied genes, before studying functionally enriched pathways. We built both transcrip-
tional and post-transcriptional regulatory networks with the goal of driving future de-
velopments towards novel anticancer target therapies. The structure of the paper is as 
follows: Methods are presented in Section 2, Results are reported in Section 3, and 
Discussion is proposed in Section 4.
2 Methods
2.1 Microarray Analysis. 
The MCF-7 cells  were  cultured in DMEM medium supplemented with 10% fetal 
bovine serum, 2 mM L-glutamine, at split ratio of 1:4 twice a week. After 24 hours of 
spit  the culture  medium was  changed  with media  containing 2,5 µM 5-Aza-2-dC 
(DAC). The treated cells were collected after 48 hours and the mRNA was extracted 
for pelleted cells. Steps for cDNA microarray analysis were: 1. Total RNA samples 
were isolated from treated/untreated cells using TRIZOL reagent (Invitrogen); 2. Con-
centration of purified RNA samples were determined by A260 measurement and the 
quality was checked by Lab-on-a-chip analysis (total RNA nano biosizing assay, Agi-
lent) with the Agilent 2100 Bioanalyzer. 
RNAs isolated from different tumor tissues, and transcribed in cDNAs, were used to 
carry out the analysis. The cDNAs from treated BC were labeled with cy5 red fluores-
cent dye and untreated BC with cy3 green fluorescent dye. Hybridization was done on 
a microarray chip called MWG Human Cancer Array containing 50-mer oligo probes 
for 1920 genes (1853 human genes associated with cancer, 27 control genes and 40 
replicated  genes).  Spots of  fluorescence  intensity were  read  by dual  laser  scanner 
(BioDiscovery) and the values were processed with Mavi Pro-2.6.0. (MWG Biotech), 
by computing background subtraction, normalization to a number of housekeeping 
genes, and comparison with untreated cancers. In order to select deregulated genes, 
we considered the cy5/cy3 normalized ratio (NR), calculated for each gene and by 
taking the ratio of the intensity in cy5  (Ic5)  and the normalized intensities in cy3  
(nIc3). Then, to reduce variability, all ratio values were transformed in log base 2. For 
inclusion of highly deregulated genes, we considered as up-regulated or down-regu-
lated genes those with log2 (NR) > 2.0 and log2 (NR) < -2.0, respectively. 
IWBBIO 2013. Proceedings Granada, 18-20 March, 2013 414
2.2 Functional Enrichment and Pathways Analysis
The analysis of the list of significantly deregulated genes is based on the F-Census 
database  [22] (http://bioinfo.hrbmu.edu.cn/fcensus/Home.jsp), to extract information 
from  highly  inconsistent  cancer  gene  data  sources  including  CGC (Cancer  Gene 
Census) [23], OMIM (Online Mendelian Inheritance in Man) [24], AGCOH(Atlas of 
Genetics and Cytogenetics in Oncology and Haematology)  [25], CancerGenes  [26], 
TSGDB  (Tumor  Suppressor  Gene  Database)  [27],  TGDBs  (Tumor  Gene  Family 
Databases) [28]. Then, two gene lists have been considered: H-list [29- 32] and R-list 
[33- 34] identified by two types of high-throughput techniques, and post-transcrip-
tional regulation predicted by some microRNA (miRNA) target prediction algorithms 
including TargetScan [35], PicTar [36], DIANA-microT [37] and MirTarget2 [38].
For bioinformatics and functional annotation, the tools that were considered were 
FatiGO, available in Babelomics [39, 40] (http://babelomics.bioinfo.cipf.es),  DAVID 
Bioinformatics [41, 42] (http://david.abcc.ncifcrf.gov/gene2gene.jsp), and also over-
representation analysis (ORA) available in ConsensusPathDB [43] (http://cpdb.mol-
gen.mpg.de/). The tool combination aimed at identifying the functional categories and 
biological pathways among the genes that were differentially expressed (DE) between 
treated and untreated BC. FatiGO, Functional annotation analysis and ORA analysis 
are tools for easy and interactive querying that perform a functional enrichment (FE) 
analysis by comparing two lists of genes (one corresponds to the list of deregulated  
genes, and the other to the list of human genome). The output links the genes to the  
corresponding annotations, found in the databases (like GO terms, KEGG, Biocarta,  
Reactome etc.). Babelomics and David Bioinformatics contain an old version of data 
sources, while  ConsensusPathDB contains the latest version of several dbs also in-
cluded in the previously listed tools.
2.3 Transcriptional and Post-transcriptional Regulatory Network Analysis
The detection of Transcription Factors (TFs) predicted to regulate the list of signific -
antly deregulated genes upon DAC treatment in Breast cancer, was performed using 
the web resource  TFactS [44] (http://www.tfacts.org/). TFactS db contains genes re-
sponsive to TFs, according to experimental evidence reported in literature. It reports 
two datasets: (i) A sign sensitive catalogue that indicates the type (up or down) of TF  
regulation exerted on its targets; (ii) A sign less catalogue that includes all regulatory 
interactions contained in sign sensitive and further interactions without the specific 
type of regulation. TFactS takes as a query the two lists of up/down regulated genes 
and compares them with sign-sensitive catalog of manually curated annotated target  
genes, then returning the lists of activated and inhibited TFs whose annotated target  
genes show a significant overlap with the query genes. 
We merged the last versions of experimentally validated miRNA-target gene data-
bases:  miRTarBase  V.2.4 [45]  (http://mirtarbase.mbc.nctu.edu.tw/),  miRecords  V.3 
[46]  (http://mirecords.biolead.org/),  and  miR2Disease  [47] (http://www.mir2dis-
ease.org/), to build a non-redundant dataset of miRNA-target genes regulatory inter-
actions in human. We used this non-redundant dataset to predict the miRNA regulat-
ors  among  the  list  of  significantly  deregulated  genes.  We  used  Cytoscape  [48] 
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(http://www.cytoscape.org/), to show the transcriptional and post-transcriptional regu-
latory  network.  For  network  analysis,  we  used  a  tool  called  “AdvancedNetwork-
Merged” merging networks by set operations (union, intersection and difference). 
3 Results
3.1 Pathway signatures after DAC treatment
Overall we have identified 336 DE genes upon DAC treatment. In particular, after 
treatment of MCF-7 cell line, we performed gene expression profiling to identify the 
epigenetically modified genes. We found 222 up-regulated genes with a log2 (NR) > 2 
and integrated them with the F-census (Table 1S). Then we found 114 down regulated 
genes with a log2  (NR) < -2 (Table 2S). The following examples from the list of top 
up-regulated genes (Table 1S) are emphasized: -CTAG1B (cancer/testis antigen 1B) 
is a member of cancer/testis (CT) antigens found expressed in normal testis and in 
many cancers [49, 50]. Thanks to the capacity of a subset of these antigens to activate 
a spontaneous cellular immune responses in cancer  patients  [51],  this makes them 
ideal  cancer  antigen  targets  for  tumor  immunotherapy,  especially  for  adult  T-cell  
leukemia/lymphoma (ATLL)  [52]; -RAB30 is a member of Ras-associated binding 
proteins (Rabs), that are involved in regulating different steps during exocytosis [53]. 
In particular Rab30 is Golgi-specific Rabs, required for the structural integrity of the 
Golgi apparatus [54]; -MAGEA1 is also one of CT antigens, in particular found ex-
pressed in 10% of tumour cells in conjunctival melanomas  [55], and is a potential 
candidate in combination with immunotherapy.
We then found the following top down-regulated genes: -CDKN2B, a cyclin-de-
pendent kinase inhibitor 2B (known also as p15, inhibits CDK4) and a key regulator 
of biological processes repressing cell cycle progression by inhibition of cdk4 and 
cdk6 [56]. The down-regulation may represent a side effect of treatment and the bal-
ance  between  DNA  methylation  and  demethylation  is  a  critical  regulator  of  the 
methylation status of cyclin-dependent kinase inhibitor [57]. In fact it is known that 
the demethylating agents function as DNA methyltransferase inhibitors and can be in-
corporated  into  the  genome during  DNA replication,  and  bind DNA methyltrans-
ferases that have the catalytic domain. This may lead to global hypomethylation and 
re-expression of both tumor suppressor genes and misregulation of proto-oncogenes 
[58]; - CDH6 (cadherin 6) is a membrane glycoprotein and a member of the cadherin 
superfamily type II involved in cell-cell adhesion, differentiation and morphogenesis. 
The aberrant  expression of cadherin-6 correlates with a poor prognosis  in patients 
with E-cadherin-absent Renal cell carcinomas (RCC) and could be a useful tool to es-
timate the malignancy potential of the tumor  [59]; -  CDH7 (cadherin 7) is another 
member of the cadherin superfamily type II. It was shown that CDH7 play a role in  
tumor development of malignant melanoma cells by interacting with melanoma inhib-
itory activity protein (MIA) and migration melanoma cell [60].
Using different functional enrichment analysis tools, we found a list of the over-
represented functional categories and pathways referring to up- and down-regulated 
gene. The results using FatiGO are reported in Table 3S and Table 4S. The results us-
ing functional enrichment analysis by David Bioinformatics are reported in Table 5S 
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and Table 6S. The enriched pathways resulted from ORA analysis available in  con-
sensusPathDB are reported in Table 7S and Table 8S. We then used the graphical tool 
available in consensusPathDB to select the most interesting pathways involved in up- 
and down-regulated genes (Figure 1 and 2).  We next report the results obtained using 
ORA. Figure 1 shows the most interesting pathways regulated upon DAC treatment. 
A summary is reported in Table 1 together with the list of up-regulated genes in each 
specific pathway. Our result show that the top enriched pathways associated to up-
regulated  genes  are the ATM  signalling  (Ataxia  telangiectasia  mutated)  and the 
MDM2 (Mouse double minute 2), an upstream components in ATM and DNA dam-
age response mechanism.
Figure 1: The over-represented pathways among the input list of 222 up-regulated genes 
upon DAC treatment. The node size indicates the size of the gene set. The node color corres-
ponds to the p-value (deeper red means smaller P-value). The green node border is used to se-
lect the most interesting pathways. The edge width indicates the size of the overlap between 
two nodes, while the edge color represents the number of shared genes in the predefined datset. 
Table 1: The enriched pathways associated to up-regulated genes.
Pathways ID Genes p-value q-value
Atm signaling ATM; MDM2; RBBP8; JUN; TP73 3.23E-06 1.23E-03
Wnt Signaling and  Pluripo-
tency
WNT2B; PRKCH; PPP2R1B; PRKCE; 
WNT1; JUN; FRAT1
3.68E-04 1.25E-02
EPO Receptor Signaling STAT5B; PTPRU; RAF1; EPO 3.90E-04 1.25E-02
NF-kappa B signaling PTGS2; ATM; CFLAR; TNFRSF11A; 
MALT1; IL8
1.48E-03 3.11E-02
TSH signaling JUN; GNA12; RAF1; GNA13; PAX8 1.87E-03 3.36E-02
p53 signaling ATM; MDM2; PPM1D; APAF1; TP73 2.28E-03 3.60E-02
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Cytokine-cytokine receptor in-
teraction 
IFNW1; TGFB3; IL22; EPO; TNFRSF14; 
CSF2RA; TNFRSF8; TNFRSF11A; IL8; 
LIFR
3.31E-03 3.80E-02
Androgen Receptor NR2C2; CEBPA; RUNX2; JUN; FHL2; 
AHR; MDM2
3.76E-03 4.07E-02
Integrated breast cancer RAD54L; ATM; JUN; AHR; RAD50; 
MDM2; TSC1
4.36E-03 4.15E-02
Jak-STAT signaling IFNW1; IL13RA2; CSF2RA; EPO; 
STAT5B; IL22; LIFR
5.21E-03 4.30E-02
TNF alpha Signaling JUN; RIPK3; RAF1; APAF1; CFLAR 6.59E-03 4.90E-02
The mechanisms underlying the cytotoxicity of DAC treatment in gastric cancer 
AGScells was recently revealed, showing that ATM activation was associated with 
P53 phosphorylation and the cytotoxicity could be abolished using PI3K inhibitor 
[61]. In our case the ATM activation pathway is associated with the activation of p73 
which is a member of p53 tumor suppressor family, important in regulation of cell 
cycle and apoptosis after DNA damage and found inactivated in many tumor histo-
types  [62, 63]. The methylation status of p73 was shown to be common in patients  
with MDS and associated with poor prognosis [63, 64]. The p73 play also a key role 
in p53 signalling pathways exerting a anticarcinogenic effect [65]. 
The reactivation of tumor suppressor represent one of the antitumor actions of de-
methylating agent therapy. The activation of  the  Wnt Signalling and nuclear factor 
kappa  B(NFKB) pathways  are important  for  the control  of self-renewal  in normal 
stem cell and also in the biology of breast cancer stem cells [66]. However the activa-
tion of NFKB  pathway  could leads to the production of cytokines that trigger Cy-
tokine-cytokine  receptor  interaction,  differentiation  an  proliferation  signals,  all  of 
which contribute to chronic inflammation and malignant progression [67- 69]. The 
key components of thyroid stimulating hormone (TSH) signalling pathway are the up 
regulation of guanine nucleotide binding protein GNA12 and GNA13, also known as 
G12 subfamily, which mediate G protein signaling and have been implicated in vari-
ous biological and pathological processes [70]. 
The Jun TF, known also as AP-1 or c-Jun, represents a key downstream effector of 
G12 signaling pathway  [71]. PAX8 is a nuclear  protein,  involved in regulation of 
thyroid-specific genes and development of thyroid follicular cell development. The 
inhibition of Pax8 may be a very attractive targeted therapy for patients with endo-
metrial cancer  [72].  RAF1 is a protoncogene and functions downstream of the Ras 
family; it is activated in TSH and TNF alpha signaling pathway. The up regulation of 
RAF1 have been identified as predictive biomarker and new target for breast cancer 
therapy [73].  Figure  2 shows the  most  interesting  pathways  regulated  upon DAC 
treatment and a summary appears in Table 2 to show the list of down-regulated genes 
in each specific pathway. It is important to notice that DAC treatment in MCF-7 cells 
induces down-regulation of different cytokines and interferons genes that represent 
key regulators of the Cytokine-cytokine receptor interaction, PI3K-AKT, Jak-STAT 
and IL-2 signaling pathways. 
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From Table 2, IL2RA and IL-2 are the common genes among all these pathways. 
The up-regulation of the interleukin-2 (IL-2) and its receptor alpha (IL2RA) are asso-
ciated with the malignancy of the infiltrating human breast cancer [74]. It seems that 
their down-regulation could produce an anticancer effect.  The deregulation of these 
cytokines  and interferons genes may suggest  a potential  role as breast  cancer  bio-
marker or use as novel treatment in combination with DAC treatment.
Figure 2: The over-represented pathways among the input list of 114 down regulated 
genes upon DAC treatment. The node size indicates the size of the gene set. The node color 
corresponds to the p-value (deeper red means smaller P-value). The green node border is used 
to  select  the  most  interesting  pathways.  The  edge  width indicates  the  size  of  the  overlap 
between two nodes, while the edge color the number of shared genes in the predefined dataset.
Table 2: The enriched pathways associated to down-regulated genes.
Pathways ID Genes p-value q-value
Cytokine-cytokine receptor inter-
action 
IL2RA;  IFNA8;  IFNA1;  BMPR1B; 
TNFSF8; IL2; IL26; TNFRSF18.
3.54E-04 2.93E-02
Nuclear Receptor transcription NR1D1; NR2E1; RXRA; RORB 3.55E-04 2.93E-02
PI3K-Akt signaling IL2RA; IFNA8; IFNA1; THBS2; 
IL2; FGF12; TSC2; FGF20
1.61E-03 4.42E-02
Jak-STAT signaling IL2RA; IFNA1; IFNA8; IL2; IL26. 3.65E-03 7.52E-02
IL-2 signaling IL2RA; IL2 4.34E-03 7.66E-02
3.2 Transcriptional and post-transcriptional regulatory networks
We built  with the cytoscape  tool  “AdvancedNetworkMerged” the union of tran-
scriptional network resulted from TFactS analysis (Table 9S), and the miRNA regu-
latory network to show TFs and miRNAs experimentally validated as candidate regu-
lators of the epigenetically modified genes in BC (Figure 3). Then, we selected only 
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TFs up-regulated upon DAC treatment and extracted the first neighbors of the selec-
ted TFs that  resulted epigenetically modified (Figure  4).  Therefore,  the epigenetic 
profile resulting from the analysis is here described in an integrative network fashion.
The following box introduces the symbols of the next two figures.
We found that five TFs correspond to up-regulated genes. The top TF is CEBPA 
(log2 (NR) = 3.68), called CCAAT/enhancer binding protein alpha, a key TF involved 
in the regulation of cellular processes, especially in Hematopoietic system [75]. It was 
found epigenetically modified and post-transcriptionally regulated by miR-124 after 
DAC and trichostatin treatment in AML [76]. The mechanism of regulation may be 
the same also in BC (Figure 4). Also miR-138 regulates CEBPA, found to inhibit  
adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells 
[77]. We didn't find any association to BC and epigenetic status. However, we found 
that CEBPA together with RUNX2 (runt-related TF 2) activates PTGS2 (prostagland-
in-endoperoxide synthase 2), also known as cyclooxygenase-2(COX-2), which is an 
inducible enzyme responsible in the prostanoid biosynthesis and is involved in in-
flammation and mitogenesis  [78]. PTGS2 is a target for development of anticancer 
therapy, and the use of anti-inflammatory PTGS2 inhibitors represents a promising 
strategy in the treatment of solid tumors [79]. Interestingly, the up-regulation of Jun 
TF is connected to the activation of  TIMP1, which is a mettallopeptidase inhibitor 
whose  overexpression  contributes  to  antimetastatic  effect  in  BC  [80] and  to  the 
activation of NQO1 (NADPH quinone oxidoreductase 1),  playing a cytoprotective 
role and found associated to increase cell-sensitivity to BC anticancer treatment [81]. 
Another important JUN target is the SERPINB5 (serpin peptidase inhibitor clade B, 
member 5) found also up-regulated upon DAC treatment and known as an important 
suppressor  of  the  invasion  and  migration  of  cancer  cells  [82].  STAT5B  (signal 
transducer and activator of transcription 5B) is a member of the STAT family of TFs,  
normally activated in response to cytokines and growth factors signals. It  has been 
shown  that  the  regulation  of  STAT1/STAT5  signalling  pathway  mediated  by 
STAT5B is important in the regulation of essential functions in the mammary gland 
[83]. The TFact tool reported among the up-regulated target of STAT5B the DPAGT1 
target, which is an enzyme that catalyzes glycoprotein biosynthesis and was found to 
be targeted also by wnt/β-Catenin signalling pathways, mediating a variety of critical 
developmental processes [84].
Gene DE: red( up-regulated), green(down-
regulated);
miRNA: border color reflects the presence of miR-family.
TF: red (activated) and green 
(inhibited);
TF activation; TF repression; miRNA repression; 
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Figure 3: The global network resulted from the union of transcriptional and post-transcrip-
tional networks.  Node shape indicates the physical entity (ellipse for epigenetically modified 
genes, Hexagon for TFs and Diamond for miRNAs). Node color indicates the differentially ex-
pressed genes (red for up-regulated genes and green for down-regulated genes).  Node border  
color indicate the significant TFs enriched (with p value<0.05) from TFactS analysis (red for 
activated TFs and green for inhibited TFs). The non-colored nodes correspond to TFs that reg-
ulate at least one target of the epigenetically modified genes.
Figure 4: Selected first neighbors of TF epigenetically modified genes from Figure 3.
4 Discussion
The improved curation of database reporting pathway definitions and regulatory in-
teractions allowed to to draw a representative picture of the major gene players and 
pathway landscape that are regulated in DAC treatment in BC. The dissection of the 
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key pathways and the knowledge of the interconnections between its components, are 
fundamental to conceive new therapeutic approaches. 
Our results are in agreement with other studies that showed the mechanism under-
lying the anticancer effect of DAC treatment and its involvement in activation ATM-
p53 signalling pathways in cancer cell lines [61] and oncogenic pathways in MCF-7 
brest cancer cells  [19]. The identification of a potential TF-miRNA regulatory net-
work contributes to shed light on the potential molecular mechanism played by DAC 
treatment in MCF-7 BC. One of this molecular mechanism is the activation of an im-
portant TF, the CEBPA and its post-transcriptional regulator miR-124 by demethylat -
ing agent, suggested as predictors for effectiveness of epigenetic therapy in AML [76] 
and that could be further investigated also in breast cancer. 
All these evidences might help the design of new therapeutic formulations, and to 
find the best  therapeutic  combinations between the use of  demethylating agent  as 
DAC and immonotherapy, e.g directly targeting the CT antigens the cancer antigens 
or other therapeutic tools that could improve the anticancer effect of the demethylat -
ing agent, obtaining therefore more efficient therapy for breast cancer. Moreover, we 
are confident that gene expression and pathway signatures could give aid to the dis-
covery of relevant connections among molecular mechanisms and drugs so as to sig-
nificantly contribute to the improvement of drug for cancer therapy. 
As a follow up agenda for future research, we are planning to extend our analysis 
to other tumor histotypes that are already available, and also to use novel gene expres-
sion profiling (exploiting transcriptome landscapes from RNA-Seq) for refinement of 
pathway signatures.
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